You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Piramal Critical Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for PIRAMAL CRITICAL

PIRAMAL CRITICAL has thirteen approved drugs.



Summary for Piramal Critical
US Patents:0
Tradenames:12
Ingredients:12
NDAs:13

Drugs and US Patents for Piramal Critical

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Piramal Critical MITIGO morphine sulfate INJECTABLE;INJECTION 204393-002 Jul 16, 2018 AP RX No No ⤷  Try for Free ⤷  Try for Free
Piramal Critical GLYCOPYRROLATE glycopyrrolate INJECTABLE;INJECTION 210842-001 Oct 25, 2018 AP RX No No ⤷  Try for Free ⤷  Try for Free
Piramal Critical DEXMEDETOMIDINE HYDROCHLORIDE dexmedetomidine hydrochloride INJECTABLE;INJECTION 214794-001 Sep 3, 2021 DISCN No No ⤷  Try for Free ⤷  Try for Free
Piramal Critical GABLOFEN baclofen INJECTABLE;INTRATHECAL 022462-001 Nov 19, 2010 AP RX Yes Yes ⤷  Try for Free ⤷  Try for Free
Piramal Critical GABLOFEN baclofen INJECTABLE;INTRATHECAL 022462-002 Nov 19, 2010 AP RX Yes Yes ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for PIRAMAL CRITICAL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 200 mcg/vial ➤ Subscribe 2015-05-01
➤ Subscribe for Injection 100 mcg/vial and 500 mcg/vial ➤ Subscribe 2015-04-14
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Piramal Critical Market Analysis and Financial Projection

Pharmaceutical Competitive Landscape Analysis: Piramal Critical Care – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, Piramal Critical Care (PCC) has emerged as a significant player, carving out a niche for itself in the critical care segment. As we delve into the competitive landscape, we'll explore PCC's market position, strengths, and strategic insights that have propelled it to the forefront of the industry.

Piramal Critical Care: An Overview

Piramal Critical Care, a division of Piramal Pharma Limited (PPL), has established itself as a global leader in hospital generics and complex hospital products. With a presence in over 100 countries and a portfolio of more than 35 products, PCC has become a trusted name in the pharmaceutical industry[1].

Core Business Focus

PCC specializes in:

  1. Inhalation anesthesia
  2. Injectable anesthesia and pain management
  3. Intrathecal therapy
  4. Other injectable products

This focused approach has allowed PCC to develop deep expertise in critical care solutions, setting it apart from more diversified pharmaceutical companies.

Market Position and Global Presence

Piramal Critical Care has secured a strong market position, particularly in the inhalation anesthesia segment. Let's break down its global presence:

North American Market

The United States represents a significant portion of PCC's revenue, accounting for approximately 51% of its Complex Hospital Generics (CHG) segment revenue in FY2024[5]. This strong foothold in the world's largest pharmaceutical market underscores PCC's competitive edge.

European Presence

Europe contributes about 16% to PCC's CHG revenue[5], indicating a substantial presence in this key market. The company's ability to navigate the diverse regulatory landscapes of European countries speaks to its operational prowess.

Emerging Markets

While specific figures for emerging markets aren't provided, PCC's presence in over 100 countries suggests a significant footprint in developing economies. This global diversification helps mitigate risks associated with market-specific fluctuations.

"Piramal Critical Care is the third largest producer of USFDA, UKMHRA and other regulators approved Inhaled Anesthetics and a global player in hospital generics."[1]

Strengths and Competitive Advantages

Piramal Critical Care's success can be attributed to several key strengths:

1. Product Portfolio Diversity

With over 35 hospital-focused products, PCC offers a comprehensive range of critical care solutions. This diversity not only caters to various medical needs but also helps in risk mitigation through product diversification.

2. Regulatory Compliance

PCC has maintained an impeccable regulatory track record, with zero Official Action Indicated (OAI) observations from the USFDA since 2011[5]. This stellar compliance history enhances customer trust and facilitates easier market access.

3. Manufacturing Excellence

The company boasts state-of-the-art manufacturing facilities in the US and India, which have consistently passed inspections by regulatory bodies like the US FDA and UK MHRA[1]. This manufacturing prowess ensures product quality and supply chain reliability.

4. Global Workforce

PCC's workforce of over 400 employees across 16 countries[6] provides a diverse talent pool and local market insights, crucial for navigating the complexities of global pharmaceutical markets.

5. Research and Development Focus

Piramal Enterprises, PCC's parent company, allocated approximately ₹1,200 crore (about $160 million) for R&D in FY23[3]. This significant investment in innovation helps PCC stay ahead of the curve in product development.

Strategic Insights and Future Outlook

To maintain and enhance its competitive position, Piramal Critical Care has adopted several strategic initiatives:

1. Expansion into Specialty and Complex Generics

PCC is focusing on expanding its product pipeline in specialty and complex generics markets. This move aims to capture higher-margin segments and differentiate from competitors[3].

2. Geographical Expansion

The company is strategically expanding its geographic footprint, with a particular focus on North America and Europe. This expansion is expected to drive future growth and increase market share[3].

3. Leveraging Technology and Automation

PCC is investing in artificial intelligence and automation to enhance operational efficiency, particularly in areas like management reviews and data analysis[7].

4. Quality-Driven Culture

The company has shifted from a compliance-driven to a culture-driven quality approach, emphasizing systems, processes, technology, and people. This focus on quality as a cultural priority helps build customer trust and strengthen brand reputation[7].

5. Strategic Partnerships

In 2023, PCC announced a collaboration with a leading global life sciences firm to co-develop innovative therapies targeted at oncology. Such partnerships are expected to contribute significantly to future revenue streams[3].

Competitive Landscape Analysis

While Piramal Critical Care has carved out a strong position for itself, it operates in a highly competitive landscape. Let's examine how it stacks up against some key competitors:

1. Market Share Comparison

In the global pharmaceutical generics market, Piramal holds a market share of 2.3% as of 2023. This is lower compared to competitors like Sun Pharma and Dr. Reddy's, which have market shares of 7.6% and 6.1% respectively[2].

2. Revenue Growth

Analysts forecast a revenue CAGR of 15% from FY23 to FY27 for Piramal Enterprises[3]. This projected growth rate indicates a positive outlook for PCC's future market position.

3. Profitability Metrics

Piramal Enterprises, PCC's parent company, outperforms industry averages in key profitability metrics:

Metric Piramal Enterprises Industry Average
Gross Profit Margin 34.3% 30.0%
Operating Profit Margin 22.1% 18.0%
Net Profit Margin 15.4% 12.0%

These figures suggest that PCC benefits from efficient operations and strong pricing power[3].

Challenges and Areas for Improvement

Despite its strengths, Piramal Critical Care faces several challenges:

1. Intense Competition

The pharmaceutical industry is highly competitive, with both established players and new entrants vying for market share. PCC must continuously innovate to maintain its position.

2. Regulatory Pressures

The pharmaceutical industry is subject to stringent regulations. While PCC has a strong compliance record, navigating evolving regulatory landscapes remains a constant challenge.

3. Market Share in High-Growth Segments

PCC's presence in high-growth segments like biopharmaceuticals remains minimal[2]. Expanding into these areas could be crucial for future growth.

4. Economic Vulnerabilities

As part of Piramal Enterprises, PCC is indirectly exposed to economic fluctuations affecting the financial services and real estate sectors, which form a significant part of the parent company's portfolio[2].

Future Outlook and Growth Opportunities

Despite the challenges, Piramal Critical Care is well-positioned for future growth:

1. Growing Global Demand

The global pharmaceutical market is projected to reach around $1.96 trillion by 2027, growing at a CAGR of about 5.5% from 2022 to 2027[3]. This overall market growth presents significant opportunities for PCC.

2. Emerging Markets Potential

Pharmaceutical sales in emerging markets could exceed $400 billion by 2025[3]. PCC's existing presence in over 100 countries positions it well to capitalize on this growth.

3. Digital Health Opportunities

The digital health market is projected to reach $660 billion by 2025, growing at a CAGR of 25%[3]. PCC could explore opportunities in this space to complement its existing product portfolio.

4. Strategic Acquisitions

The ongoing trend of consolidation in the pharmaceutical sector provides opportunities for PCC to enhance its market presence through strategic acquisitions[3].

Key Takeaways

  1. Piramal Critical Care has established a strong global presence, particularly in inhalation anesthesia and complex hospital generics.

  2. The company's strengths lie in its diverse product portfolio, strong regulatory compliance, manufacturing excellence, and focus on research and development.

  3. PCC outperforms industry averages in key profitability metrics, indicating operational efficiency and strong pricing power.

  4. Future growth strategies include expansion into specialty and complex generics, geographical expansion, and leveraging technology and automation.

  5. Challenges include intense competition, regulatory pressures, and limited presence in high-growth segments like biopharmaceuticals.

  6. Opportunities for future growth exist in the expanding global pharmaceutical market, emerging markets, and potential strategic acquisitions.

  7. PCC's focus on quality as a cultural priority and its investment in innovation position it well for future success in the competitive pharmaceutical landscape.

FAQs

  1. Q: What is Piramal Critical Care's main focus in the pharmaceutical industry? A: Piramal Critical Care specializes in complex hospital generics, with a focus on inhalation anesthesia, injectable anesthesia and pain management, intrathecal therapy, and other injectable products.

  2. Q: How does Piramal Critical Care's market share compare to its competitors? A: In the global pharmaceutical generics market, Piramal holds a market share of 2.3% as of 2023, which is lower compared to competitors like Sun Pharma (7.6%) and Dr. Reddy's (6.1%).

  3. Q: What are some of Piramal Critical Care's key strengths? A: PCC's key strengths include a diverse product portfolio, strong regulatory compliance, manufacturing excellence, a global workforce, and a significant focus on research and development.

  4. Q: What growth strategies is Piramal Critical Care pursuing? A: PCC is focusing on expanding into specialty and complex generics markets, geographical expansion (particularly in North America and Europe), leveraging technology and automation, and pursuing strategic partnerships.

  5. Q: What are the main challenges facing Piramal Critical Care in the competitive landscape? A: The main challenges include intense competition in the pharmaceutical industry, ongoing regulatory pressures, limited presence in high-growth segments like biopharmaceuticals, and indirect exposure to economic fluctuations through its parent company's diverse portfolio.

Sources cited: [1] https://www.piramal.com/businesses/piramal-pharma/critical-care/ [2] https://canvasbusinessmodel.com/products/piramal-enterprises-swot-analysis [3] https://dcfmodeling.com/blogs/health/pelns-financial-health [5] https://www.icra.in/Rating/GetRationalReportFilePdf?id=130614 [6] https://piramalcriticalcare.com/about/ [7] https://www.piramalpharmasolutions.com/about-us/quality

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.